[Steroids-induced osteoporosis due to the treatment for Pulmonary diseases.]

Clinical calcium Pub Date : 2016-01-01
Nobuyuki Horita, Takeshi Kaneko
{"title":"[Steroids-induced osteoporosis due to the treatment for Pulmonary diseases.]","authors":"Nobuyuki Horita, Takeshi Kaneko","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Corticosteroids are key medications to treat pulmonary diseases. A variety of medications, doses, administration route, and duration of corticosteroids were chosen for each of pulmonary diseases. Although corticosteroids are potent medications, they often cause serious adverse effects such as osteoporosis, diabetes, and immunosuppression. Thus, physicians have to properly assess the risk of adverse effects to prevent them. In this review, we discuss the risk of osteoporosis by corticosteroids that are prescribed for pulmonary diseases. Inhaled corticosteroids are not serious risk factors of osteoporosis. If systemic corticosteroids are planned to be administrated in the prednisolone equivalent dosage of 5 mg/day or more for three months or longer, risk of bone fracture have to be assessed regardless of the primary pulmonary disease. If necessary, prophylactic agent such as bisphosphonates should be prescript.</p>","PeriodicalId":502100,"journal":{"name":"Clinical calcium","volume":"26 10","pages":"1459-1465"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical calcium","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Corticosteroids are key medications to treat pulmonary diseases. A variety of medications, doses, administration route, and duration of corticosteroids were chosen for each of pulmonary diseases. Although corticosteroids are potent medications, they often cause serious adverse effects such as osteoporosis, diabetes, and immunosuppression. Thus, physicians have to properly assess the risk of adverse effects to prevent them. In this review, we discuss the risk of osteoporosis by corticosteroids that are prescribed for pulmonary diseases. Inhaled corticosteroids are not serious risk factors of osteoporosis. If systemic corticosteroids are planned to be administrated in the prednisolone equivalent dosage of 5 mg/day or more for three months or longer, risk of bone fracture have to be assessed regardless of the primary pulmonary disease. If necessary, prophylactic agent such as bisphosphonates should be prescript.

[治疗肺部疾病引起的类固醇性骨质疏松症]
皮质类固醇是治疗肺部疾病的关键药物。为每一种肺部疾病选择了各种药物、剂量、给药途径和糖皮质激素的持续时间。虽然皮质类固醇是有效的药物,但它们经常引起严重的不良反应,如骨质疏松症、糖尿病和免疫抑制。因此,医生必须正确评估不良反应的风险,以预防它们。在这篇综述中,我们讨论了用于肺部疾病的皮质类固醇导致骨质疏松的风险。吸入皮质类固醇不是骨质疏松症的严重危险因素。如果全身性皮质类固醇计划以泼尼松龙等效剂量5mg /天或以上给药,持续3个月或更长时间,必须评估骨折的风险,无论原发性肺部疾病如何。必要时,应开双膦酸盐等预防性药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信